Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BeOne MedicinesONC +1.53%79 Earnings per Share (Diluted) is $5.59 as of Jun. 2026. GuruFocus rates ONC with a GF Score™ of 79/100 and a GF Value™ of $376.87 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,162 Biotechnology companies, BeOne Medicines ranks worse than 86058.43% on this metric.
BeOne Medicines's EPS (Basic) for the
three
months ended in Jun. 2026 was $2.08.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 was $5.98.
During the past 13 years, BeOne Medicines's highest 3-Year average EPS without NRI Growth Rate was 27.00% per year. The lowest was -198.90% per year. And the median was -60.00% per year.
BeOne Medicines (NAS:ONC) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
BeOne Medicines Earnings per Share (Diluted) Related Terms
BeOne Medicines Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for BeOne Medicines's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BeOne Medicines Earnings per Share (Diluted) Chart
ONC vs ALNY, RVMD, RPRX: Earnings per Share (Diluted) Comparison
For the Biotechnology subindustry, BeOne Medicines's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BeOne Medicines PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BeOne Medicines's PE Ratio distribution charts can be found below:
* The bar in red indicates where BeOne Medicines's PE Ratio falls into.
BeOne Medicines Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
BeOne Medicines's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.59
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $5.59 mean?
BeOne Medicines (ONC) has a Earnings per Share (Diluted) of $5.59 as of Jun. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on BeOne Medicines and its competitors. According to the industry distribution chart, BeOne Medicines ranks #999999 out of 1162 companies in the Biotechnology industry.
Is BeOne Medicines' Earnings per Share (Diluted) too high?
BeOne Medicines' current Earnings per Share (Diluted) is $5.59. The Biotechnology industry median Earnings per Share (Diluted) is 16.20. BeOne Medicines' value of $5.59 is 65.5% below this industry median. Based on the distribution chart, BeOne Medicines ranks #999999 out of 1162 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BeOne Medicines has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' Earnings per Share (Diluted) compare to ALNY and RVMD?
According to the Biotechnology industry distribution chart, BeOne Medicines ranks #999999 out of 1162 companies for Earnings per Share (Diluted). This places BeOne Medicines in the lower half of its industry. The industry median Earnings per Share (Diluted) is 16.20. BeOne Medicines' value of $5.59 is 65.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Biotechnology company?
The median Earnings per Share (Diluted) among Biotechnology companies is 16.20, based on 1,162 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BeOne Medicines's current Earnings per Share (Diluted) of $5.59 is 65.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on BeOne Medicines and its competitors. For the Biotechnology industry, the median Earnings per Share (Diluted) is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BeOne Medicines's current Earnings per Share (Diluted) is $5.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
Based on GuruFocus' analysis, BeOne Medicines (ONC) is currently considered Fairly Valued. The stock's GF Value™ is $376.87, compared to a current price of $377.66 — trading 0.2% above its estimated fair value. The current Earnings per Share (Diluted) is $5.59 and 65.5% below the Biotechnology industry median of 16.20. BeOne Medicines' overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For BeOne Medicines (ONC), the current Earnings per Share (Diluted) is $5.59 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BeOne Medicines (ONC) Overvalued in 2026?
Based on GuruFocus' analysis, BeOne Medicines stock appears to be overvalued.
The current stock price of $377.66 is trading 0.2% above its estimated GF Value™ of $376.87.
GuruFocus considers BeOne Medicines to be Fairly Valued.
Key valuation signals for ONC:
Earnings per Share (Diluted): $5.59
GF Value™: $376.87 vs. price of $377.66 (0.2% above fair value)
Industry Position: 65.5% below the Biotechnology median (#999999 of 1162)
No single metric tells the full story. See the ONC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
79GF Score
Get the complete analysis for ONC
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ONC has been successfully added to your 
